PORTAL: a phase 2 trial testing polatuzumab vedotin, obinutuzumab and glofitamab in adults with relapsed or refractory large B-cell lymphoma

This phase 2 trial aims to test the new combination of drugs, polatuzumab vedotin, glofitamab and obinutuzumab in people with large B-cell lymphoma (LBCL) that has come back after (relapsed) or not responded (refractory) to treatment.

You can share the following clinicaltrials.gov Identifier with your medical team so they can find out more about the trial: NCT06071871

Trial aim and background  

The aim of this trial is to test the combination of drugs glofitamab, polatuzumab vedotin and obinutuzumab (Pola-Glofit) in people with relapsed or refractory LBCL. It will see how safe and effective it is before and after CAR-T therapy.

The trial will take place in two parts:

  1. Will assess the effectiveness of Pola-Glofit as a bridging treatment to CAR-T therapy in people with relapsed or refractory LBCL
  2. Will assess the effectiveness of Pola-Glofit in people with relapsed or refractory LBCL who have not improved after CAR-T therapy. 

Who can enter 

Adults with diffuse large B-cell lymphoma, high grade B-cell lymphoma, primary mediastinal B-cell lymphoma or transformed follicular lymphoma which has relapsed or is refractory to treatment may be eligible for this trial.

Locations 

Recruitment is taking place at the following UK locations:

  • University College London Hospitals, London
  • The Christie, Manchester
  • Kings College Hospital NHS Foundation Trust, London
  • Churchill Hospital, Oxford
  • Nottingham University Hospitals NHS Trust, Nottingham

Further information 

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/study/NCT06071871

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.